IPCIF Intellipharmaceutics International Inc - Ordinary Shares

0.16
-0.01  -7%
Previous Close 0.17
Open 0.16
Price To Book 5.49
Market Cap 3,546,988
Shares 22,085,856
Volume 124,574
Short Ratio 0.39
Av. Daily Volume 474,249
Stock charts supplied by TradingView

NewsSee all news

  1. Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

    TORONTO, ON / ACCESSWIRE / January 16, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the

  2. Intellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

    TORONTO, ON / ACCESSWIRE / December 5, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the

  3. Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER

    TORONTO, ON / ACCESSWIRE / November 25, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the

  4. Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi

    TORONTO, ON / ACCESSWIRE / November 18, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company") and Drs. Isa and Amina Odidi announce that,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Advisory Committee Meeting January 15, 2020 voted 24-2 against recommending approval.
Aximris XR (Oxycodone Hydrochloride extended release)
Pain relief

Latest News

  1. Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

    TORONTO, ON / ACCESSWIRE / January 16, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the

  2. Intellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

    TORONTO, ON / ACCESSWIRE / December 5, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the

  3. Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER

    TORONTO, ON / ACCESSWIRE / November 25, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the

  4. Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi

    TORONTO, ON / ACCESSWIRE / November 18, 2019 / Intellipharmaceutics International Inc. (OTCQB:IPCIF, TSX:IPCI) ("Intellipharmaceutics" or the "Company") and Drs. Isa and Amina Odidi announce that,